Cambridge, MA, January 2, 2010 - Intelligent Medical Devices, Inc. (IMDx) announced the issuance of European Patent No. EP 1397679 directed to personalized medicine for methods for determination of the cause of one or more medical symptoms in an affected individual.
The patented methods utilize multiple probes specific for targets associated with different known causes of one or more medical symptoms. Biological samples can then be screened in parallel across the probes and interactions are detected and analyzed to determine the cause of medical symptoms.
This technology provides a vast amount of information that enables rapid disease diagnosis and evaluation of treatment options. Symptomatic patients will benefit significantly from a faster and more accurate diagnosis using these methods
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
For more information, please contact Sarah Toomey at +1-617-871-6431 or stoomey@intelligentmdx.com